Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN

Watchlist Manager
Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Watchlist
Price: 49.04 USD -2.62% Market Closed
Market Cap: 4.8B USD
Have any thoughts about
Biohaven Pharmaceutical Holding Company Ltd?
Write Note

Biohaven Pharmaceutical Holding Company Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biohaven Pharmaceutical Holding Company Ltd
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Operating Income
-$436.1m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%

See Also

What is Biohaven Pharmaceutical Holding Company Ltd's Operating Income?
Operating Income
-436.1m USD

Based on the financial report for Dec 31, 2023, Biohaven Pharmaceutical Holding Company Ltd's Operating Income amounts to -436.1m USD.

What is Biohaven Pharmaceutical Holding Company Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-56%

Over the last year, the Operating Income growth was 23%. The average annual Operating Income growth rates for Biohaven Pharmaceutical Holding Company Ltd have been -56% over the past three years .

Back to Top